Increased β-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir

被引：29

作者：

Papaleo, Andrea

Warszawski, Josiane

Salomon, Remi

Jullien, Vincent

Veber, Florence

Dechaux, Michele

Blanche, Stephane

机构：

[1] Hop Necker Enfants Malad, Assistance Publ Hop Paris, Unite Immunol Hematol Pediat, F-75743 Paris 15, France

[2] Univ Paris 05, Fac Med Rene Descartes, EA 3620, Paris, France

[3] Hop Bicetre, APHP, Paris, France

[4] INSERM, U569, Paris, France

[5] Univ Paris 05, Hop Necker Enfants Malad, APHP, Serv Nephrol Pediat, Paris, France

[6] Hop St Vincent de Paul, APHP, Pharmacol Lab, F-75674 Paris, France

[7] Univ Paris 05, Hop Necker Enfants Malad, APHP, Physiol Lab, Paris, France

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2007年 / 26卷 / 10期

关键词：

HIV; children; tenofovir; beta-2-microglobulinuria; proximal tubulopathy;

D O I：

10.1097/INF.0b013e3181256570

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A single-center cross sectional evaluation of beta-2 microglobinuria as a marker of proximal renal tubule damage in 92 HIV-infected children showed that tenofovir treatment was significantly associated with very high abnormal values. In view of the very long duration of treatments for HIV infection, their possible consequences for the child's growing body should be carefully evaluated.

引用

页码：949 / 951

页数：3

共 10 条

[1] Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs [J].

Cihlar, T ;

Ho, ES ;

Lin, DC ;

Mulato, AS .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2001, 20 (4-7) :641-648

[2]

Côté HCF, 2006, ANTIVIR THER, V11, P79

[3] Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children [J].

Gafni, Rachel I. ;

Hazra, Rohan ;

Maldarelli, Frank ;

Tullio, Antonella N. ;

DeCarlo, Ellen ;

Worrell, Carol J. ;

Flaherty, John F. ;

Yale, Kitty ;

Kearney, Brian P. ;

Zeichner, Steven L. .

PEDIATRICS, 2006, 118 (03) :E711-E718

[4] Urinary β2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil furnarate [J].

Gatanaga, Hiroyuki ;

Tachikawa, Natsuo ;

Kikuchi, Yoshimi ;

Teruya, Katsuji ;

Genka, Ikumi ;

Honda, Miwako ;

Tanuma, Junko ;

Yazaki, Hirohisa ;

Ueda, Akihiro ;

Kimura, Satoshi ;

Oka, Shinichi .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (08) :744-748

[5] A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children [J].

Giacomet, V ;

Mora, S ;

Martelli, L ;

Merlo, M ;

Sciannamblo, M ;

Viganó, A .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (04) :448-450

[6] Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir [J].

Hussain, Sabiha ;

Khayat, Abeer ;

Tolaymat, Asad ;

Rathore, Mobeen H. .

PEDIATRIC NEPHROLOGY, 2006, 21 (07) :1034-1036

[7] Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy [J].

Izzedine, Hassane ;

Hulot, Jean-Sebastien ;

Villard, Eric ;

Goyenvalle, Catherine ;

Dominguez, Stephanie ;

Ghosn, Jade ;

Valantin, Marc Antoine ;

Lechat, Philippe ;

Deray, Gilbert .

JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (11) :1481-1491

[8] Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels [J].

Kinai, E ;

Hanabusa, H .

AIDS, 2005, 19 (17) :2031-2033

[9] Tenofovir disoproxil fumarate - A review of its use in the management of HIV infection [J].

Lyseng-Williamson, KA ;

Reynolds, NA ;

Plosker, GL .

DRUGS, 2005, 65 (03) :413-432

[10] HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy [J].

Röling, J ;

Schmid, H ;

Fischereder, M ;

Draenert, R ;

Goebel, FD .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (10) :1488-1495

← 1 →